ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits

The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment.